NCT00144976已完成不适用
Pilot Study, Without Direct Individual Benefice, of Biological Effect of Tarceva (OSI-774) at Posology of 150 mg by Day for Patients Stricken by ENT Epidermoid Carcinoma Waiting for First Surgical Picking up.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 43
- 试验地点
- 2
- 主要终点
- To evaluate the biological effect of Tarceva (OSI-774) from an inhibition of EGF tumor receptor tyrosine kinase activity's point of view, for patients who are carriers of head and neck epidermoid carcinoma.
研究概览
简要总结
The purpose of this study is to evaluate the biological effect of Tarceva (OSI-774) from an inhibition of EGF tumor receptor tyrosine kinase activity's point of view, for patients who are carriers of head and neck epidermoid carcinoma.
详细描述
Patients will receive Tarceva in continuous between 18 and 28 days after pan-endoscopy exam until surgery
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Neck and head epidermoid carcinoma histologically proved. Patient with an ENT epidermoid tumor can be included in the study if this relapse is located in an area not irradiated yet.
- •At least tumor classified T2NXM0
- •Patient who can be picked up in a first surgery with a curative purpose or who must have a necessity's surgery (cervical curettage for voluminous adenopathies before radiotherapy)
- •Patient without clinical or radiological sign of metastatic disease
- •Good general status (OMS ≤ 2)
- •Patient able to ingest food.
- •Age ≥ 18 years
- •Well-informed written consent, signed by the patient.
- •Patient with sickness benefit
排除标准
- •Patient with relapse ever treated by radiotherapy
- •Other prospective study's participation
- •Recent and massive digestive haemorrhage
- •Medical contra-indication like main general status alteration, uncontrolled serious infectious disease, main uncontrolled metabolic anomaly ongoing.
- •Pre-existent pulmonary pathology (BPCO, pleurisy, lymphangitis, interstitial syndrome)
- •Severe cardiac pathology (stage 3 or 4 cardiac insufficiency, unstable angina pectoris, uncontrolled arrhythmia, myocardium's infarction antecedent during the year that precede the inclusion.
- •Ophthalmic pathology antecedent concerning the ocular surface or lens-carrier
- •Concomitant administration, by local or general tract, of drug responsible for ocular drought or which could delay the epithelial cicatrization
- •Less than 1000 polynuclear neutrophil leucocytes or less than 75000 blood-platelets at inclusion
- •Bilirubin at higher concentration than one point five times the normal
- •Renal insufficiency (glomerular filtration flow ≤ 40 ml/min)calculated in accordance with Cockroft's formula
- •Tacking of Beta blockers, amiodarone, NSAIDs, bleomycin, just before or during the study
- •Pregnant or nursing women
- •Patient under guardianship or trusteeship.
结局指标
主要结局
To evaluate the biological effect of Tarceva (OSI-774) from an inhibition of EGF tumor receptor tyrosine kinase activity's point of view, for patients who are carriers of head and neck epidermoid carcinoma.
次要结局
- Correlation study between pharmacokinetic and biological effect observed of molecule OSI-774.
- Verification of biological effect of Tarceva's homogeneity (inhibition of EGFR-TK) according to sites, particularly from the point of view of a possible difference primary tumor/metastatic adenopathy and tumorous tissue/healthy tissue.
- Characterisation of OSI-774 modes of action from the cellular cycle arrest proteinic effectors's point of view.
- Constitution of frozen tissue bank for genomic (sequencing) study of tumorous EGF-R structure and for modification of in situ gene expression induction with OSI-774 by RNA microarrays technology.
- Pharmacogenomics study of Tarceva's metabolism : genes studied code for cytochrome 3A5 and glycoprotein-P.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell CancerHead and Neck CancerNCT00076310M.D. Anderson Cancer Center50
已完成
2 期
Tarceva and Capecitabine for Pancreatic CancerNeoplasm MetastasisPancreatic CancerNCT00125021Dana-Farber Cancer Institute32
已完成
2 期
Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal CancerNeoplasm MetastasisColorectal CancerNCT00123851Dana-Farber Cancer Institute32
已完成
2 期
OSI-774 (Erlotinib, Tarceva) in Elderly PatientsNon-Small Cell Lung CancerNCT00200395Montefiore Medical Center30
已完成
2 期
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung CancerBrain CancerNon-small Cell Lung CancerNCT00871923M.D. Anderson Cancer Center44